Biochemical remission after resection of prostate cancer lung metastasis.
Once metastatic, prostate cancer was regarded as a systemic disease that is not amenable to surgical therapy. We present a case of a solitary pulmonary recurrence of prostate cancer after radical prostatectomy that was resected, resulting in 12 years of biochemical remission without additional therapy.
Chao
Debby H
DH
Department of Urology, Stanford University School of Medicine, Stanford, California, USA.
Higgins
John P T
JP
Brooks
James D
JD
D000230:Adenocarcinoma / Q000097:blood / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery; D000368:Aged; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000097:blood*; D003131:Combined Modality Therapy; D003371:Cough; D018572:Disease-Free Survival; D004417:Dyspnea / Q000209:etiology; D005485:Flutamide / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D016729:Leuprolide / Q000627:therapeutic use; D008175:Lung Neoplasms / Q000097:blood / Q000188:drug therapy / Q000556:secondary* / Q000601:surgery; D008297:Male; D009363:Neoplasm Proteins / Q000097:blood*; D011013:Pneumonectomy; D017430:Prostate-Specific Antigen / Q000097:blood*; D011468:Prostatectomy; D011471:Prostatic Neoplasms / Q000097:blood / Q000601:surgery*; D012074:Remission Induction
D018931:Antineoplastic Agents, Hormonal; D014408:Biomarkers, Tumor; D009363:Neoplasm Proteins; D005485:Flutamide; D017430:Prostate-Specific Antigen; D016729:Leuprolide